Olema Pharmaceuticals to Present at Upcoming Investor Conferences

Got story updates? Submit your updates here. ›

San Francisco-based Olema Oncology has announced upcoming appearances at several major investor conferences in February 2026, including the Guggenheim Securities Emerging Outlook: Biotech Summit, Citi's 2026 Virtual Oncology Leadership Summit, and Oppenheimer's 36th Annual Healthcare Life Sciences Conference. This signals the company's efforts to attract investment as it develops innovative breast cancer therapies targeting the estrogen receptor and other novel pathways.

Why it matters

Olema's pipeline reflects a broader trend in oncology towards more personalized, targeted treatments. Its lead candidate, palazestrant, is a dual-action drug that combines Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD) mechanisms to overcome resistance seen with traditional hormone therapies. This approach, if successful, could transform the treatment landscape for the approximately 70% of breast cancers that are estrogen receptor-positive.

The details

Palazestrant's dual CERAN and SERD action aims to more effectively block and degrade the estrogen receptor, potentially overcoming resistance that can develop with current hormone therapies. Beyond estrogen receptor targeting, Olema's pipeline includes OP-3136, a KAT6 inhibitor that disrupts gene expression and cancer cell growth. The company's participation in investor conferences allows it to directly address concerns and articulate its vision for the future of personalized breast cancer treatment.

• Olema Oncology announced its upcoming investor conference appearances on February 5, 2026.
• The conferences Olema will attend are scheduled for February 2026.

What’s next

Investors will be closely watching Olema's Phase 3 trial results for palazestrant, as positive data could be a major catalyst for the company's stock and further investment in the targeted breast cancer therapy space.